Protein Pharmacology

Rottapharm is co-founder, with a group of academic scientists and the University of Milano (Italy), of a university spin-off (Foldless). The Company owns a revolutionary proprietary technology platform base on protein dynamic pharmacology, able to discover potential new drugs of peptidic or peptidomimetic nature for diseases in which targeted proteins have a pathogenetic role.
Foldless started to investigate different viral diseases and will move to degenerative diseases afterwards. BRU 83-92 is a selective HIV-1 protease inhibitor, endowed with a pharmacological profile far superior to that of any other known anti-viral agent. The compound will enter preclinical development in the 2nd quarter of 2010 and phase 1 clinical studies are forecasted in 2011.